Alto Neuroscience (NYSE:ANRO) Sets New 12-Month High – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares reached a new 52-week high on Thursday . The company traded as high as $29.49 and last traded at $29.1860, with a volume of 94860 shares changing hands. The stock had previously closed at $28.03.

Analysts Set New Price Targets

ANRO has been the topic of several recent analyst reports. Wedbush lifted their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wolfe Research initiated coverage on Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Finally, Wall Street Zen downgraded Alto Neuroscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Stock Performance

The stock has a market capitalization of $1.01 billion, a PE ratio of -11.92 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The business’s fifty day moving average price is $24.53 and its 200-day moving average price is $22.17.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities research analysts expect that Alto Neuroscience, Inc. will post -3.14 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience in the second quarter worth $226,000. Perceptive Advisors LLC grew its position in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after buying an additional 225,500 shares in the last quarter. Bank of America Corp DE grew its position in Alto Neuroscience by 131.5% during the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock worth $577,000 after buying an additional 14,585 shares in the last quarter. Eversept Partners LP bought a new position in Alto Neuroscience in the 1st quarter worth about $2,814,000. Finally, The Manufacturers Life Insurance Company bought a new position in Alto Neuroscience in the 1st quarter worth about $534,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.